-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The resignation of pharmaceutical executives is closely related to the company's strategy to deal with the market environme.
In recent years, under the influence of factors such as centralized procurement, industry prospects, and performance tasks, more and more executives of relevant companies have begun to choose to resi.
For example, recently, another group of companies announced on the same day that they have changed their executiv.
Beihai Kangcheng Appoints Li Ping as Senior Vice President of Clinical Development and Operations On the 11th, Beihai Kangcheng announced the appointment of Li Ping as Senior Vice President of Clinical Development and Operations, effective May 8, 202 Previously, Li Ping served as Vice President of Clinical Development at Connected Biosciences, responsible for formulating and implementing clinical development strategi.
In addition, she served as Executive Director of Clinical Operations Department of Shanghai Haihe Pharmaceutical .
, L.
and Director of Medical and Scientific Affairs Department of Servier Chi.
Li Ping has also held a number of clinical development and medical affairs positions in well-known multinational pharmaceutical compani.
The chairman of China Resources Shuanghe retired on the 11th, and China Resources Shuanghe announced that Feng Yi, the chairman of the company, will no longer serve as a director, chairman and strategy committee of the ninth board of directors of the company since May 11 because he has reached the legal retirement a.
Chairman's po.
More than half of the company's directors jointly elected the company's director and president Yu Shunting to perform the chairmanship on his behalf, starting from May 11 and ending on the date of the election of the new chairm.
Zhang Junqiang, employee representative supervisor of Foci Pharmaceuticals, resigned On the 11th, Foci Pharmaceuticals issued an announcement saying that Zhang Junqiang applied to resign from the position of employee representative supervisor of the company's seventh board of supervisors due to work adjustment, and he would no longer hold any positions in the company after his resignati.
In addition, Wang Yunjie was by-election as the employee representative supervisor of the seventh session of the Supervisory Committee of the Company, and the term of office will expire until the term of the seventh session of the Supervisory Committee of the Company expir.
Under the background of industry changes and intensified competition, the adjustment of the pharmaceutical industry will accelerate in 2022, and the changes of executives of pharmaceutical companies are becoming more freque.
It is understood that not only domestic pharmaceutical companies, but also international giants are also adjusting their structur.
For example, AstraZeneca also issued an internal announcement in April this year: Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reaso.
At the same time, Yu Qiran, the current director of new product planning and marketing, will also serve as the head of the project management office of the general manager of oncolo.
It is reported that in the past 10 months, AstraZeneca has actually had 10 executives leave, including general managers and vice presiden.
According to incomplete statistics, since the beginning of January 2022, more than 120 senior executives of pharmaceutical companies have changed, including the resignation of a large number of chairman of pharmaceutical compani.
The reasons for resignation are mainly personal reaso.
In addition, from the overall point of view, the traditional Chinese medicine industry is an area with a large number of resignatio.
In this regard, the industry believes that while the current pharmaceutical market reform is still in full swing, with the vigorous development of the domestic innovative drug market, talent is expected to become an important object of competition for various pharmaceutical companies in the futu.
In recent years, under the influence of factors such as centralized procurement, industry prospects, and performance tasks, more and more executives of relevant companies have begun to choose to resi.
For example, recently, another group of companies announced on the same day that they have changed their executiv.
Beihai Kangcheng Appoints Li Ping as Senior Vice President of Clinical Development and Operations On the 11th, Beihai Kangcheng announced the appointment of Li Ping as Senior Vice President of Clinical Development and Operations, effective May 8, 202 Previously, Li Ping served as Vice President of Clinical Development at Connected Biosciences, responsible for formulating and implementing clinical development strategi.
In addition, she served as Executive Director of Clinical Operations Department of Shanghai Haihe Pharmaceutical .
, L.
and Director of Medical and Scientific Affairs Department of Servier Chi.
Li Ping has also held a number of clinical development and medical affairs positions in well-known multinational pharmaceutical compani.
The chairman of China Resources Shuanghe retired on the 11th, and China Resources Shuanghe announced that Feng Yi, the chairman of the company, will no longer serve as a director, chairman and strategy committee of the ninth board of directors of the company since May 11 because he has reached the legal retirement a.
Chairman's po.
More than half of the company's directors jointly elected the company's director and president Yu Shunting to perform the chairmanship on his behalf, starting from May 11 and ending on the date of the election of the new chairm.
Zhang Junqiang, employee representative supervisor of Foci Pharmaceuticals, resigned On the 11th, Foci Pharmaceuticals issued an announcement saying that Zhang Junqiang applied to resign from the position of employee representative supervisor of the company's seventh board of supervisors due to work adjustment, and he would no longer hold any positions in the company after his resignati.
In addition, Wang Yunjie was by-election as the employee representative supervisor of the seventh session of the Supervisory Committee of the Company, and the term of office will expire until the term of the seventh session of the Supervisory Committee of the Company expir.
Under the background of industry changes and intensified competition, the adjustment of the pharmaceutical industry will accelerate in 2022, and the changes of executives of pharmaceutical companies are becoming more freque.
It is understood that not only domestic pharmaceutical companies, but also international giants are also adjusting their structur.
For example, AstraZeneca also issued an internal announcement in April this year: Lu Yanbin, the current deputy director of the Strategic Project Management Office, will leave the company to seek external development opportunities due to personal reaso.
At the same time, Yu Qiran, the current director of new product planning and marketing, will also serve as the head of the project management office of the general manager of oncolo.
It is reported that in the past 10 months, AstraZeneca has actually had 10 executives leave, including general managers and vice presiden.
According to incomplete statistics, since the beginning of January 2022, more than 120 senior executives of pharmaceutical companies have changed, including the resignation of a large number of chairman of pharmaceutical compani.
The reasons for resignation are mainly personal reaso.
In addition, from the overall point of view, the traditional Chinese medicine industry is an area with a large number of resignatio.
In this regard, the industry believes that while the current pharmaceutical market reform is still in full swing, with the vigorous development of the domestic innovative drug market, talent is expected to become an important object of competition for various pharmaceutical companies in the futu.
